Acadian Asset Management LLC Homology Medicines, Inc. Transaction History

Acadian Asset Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.53 - $1.14 $33,671 - $72,426	-63,532 Reduced 48.85%	66,515 $40,000
Q3 2023 Nov 13, 2023	SELL	$0.84 - $1.43 $86,517 - $147,285	-102,997 Reduced 44.2%	130,047 $151,000
Q2 2023 Aug 07, 2023	SELL	$0.83 - $1.12 $4,265 - $5,755	-5,139 Reduced 2.16%	233,044 $205,000
Q1 2023 May 11, 2023	SELL	$0.91 - $1.69 $7,142 - $13,264	-7,849 Reduced 3.19%	238,183 $244,000
Q4 2022 Feb 14, 2023	BUY	$1.09 - $2.04 $95,187 - $178,149	87,328 Added 55.03%	246,032 $309,000

Q3 2022 Nov 14, 2022	BUY	$1.55 - $3.01 $56,418 - $109,560	36,399 Added 29.76%	158,704 $255,000
Q2 2022 Aug 09, 2022	BUY	$1.39 - $3.12 $91,737 - $205,913	65,998 Added 117.21%	122,305 $241,000
Q1 2022 May 12, 2022	SELL	$2.6 - $4.17 $82,401 - $132,159	-31,693 Reduced 36.01%	56,307 $171,000
Q4 2021 Feb 10, 2022	SELL	$3.64 - $7.78 $524,979 - $1.12 Million	-144,225 Reduced 62.11%	88,000 $319,000
Q3 2021 Nov 12, 2021	SELL	$6.01 - $8.71 $1.4 Million - $2.03 Million	-232,959 Reduced 50.08%	232,225 $1.83 Million
Q2 2021 Aug 11, 2021	BUY	$6.02 - $9.64 $2.8 Million - $4.48 Million	465,184 New	465,184 $3.38 Million

66.2K

Ticker FIXX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 57,402,000
Description
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nucleas...

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Acadian Asset Management LLC with notifications on news.